Inclusion Criteria:  Mastery of Dutch language Age of ≥ 18 years of age and able to give written IC Participant agrees to be randomized Moderate to severe depression; score ≥ 26 on the Inventory of Depressive Symptoms-Self Report (IDS-SR) DSM-5 diagnosis of major depression disorder (MDD), confirmed with clinical interview (MINI)  Moderate to severe childhood trauma (CT) before the age of 18; Score above validated cut-off for moderate to severe CT on one or more of the following domains using the Childhood Trauma Questionnaire (CTQ):  physical neglect: score ≥ 10 emotional neglect: score ≥ 15 sexual abuse: score ≥ 8 physical abuse: score ≥ 10 emotional abuse: score ≥ 13  Exclusion Criteria:  Primary diagnosis of post-traumatic stress disorder (PTSD) or Acute Stress Disorder (ASD) Lifetime diagnosis of borderline personality disorder (BPD) Other lifetime severe psychiatric comorbidity (e.g. bipolar disorder, schizophrenia) or current alcohol/drug dependence that requires clinical attention. Start of other forms of depression treatment in the week before or after the start of the intervention. Female participant being a WOCBP and who does not want to use a non-hormonal contraceptive method (e.g. condom) during the intervention period and up to 1 month after the intervention. Female participants that are pregnant or breastfeeding. Female participants that have a history of unexplained vaginal bleeding or endometrial changes. Chronic adrenal insufficiency (contraindication for mifepristone).  Current use of:  Medications containing CYP3A4-inhibitors Medications containing CYP3A4-inductors Glucocorticoid antagonists within 1 week before possible start of trial treatment. Systemic corticosteroids. Topical corticosteroid treatment are acceptable, with the exception of inhaled corticosteroids (inhalators).